Yersinia pestis activates both IL-1β and IL-1 receptor antagonist to modulate lung inflammation during pneumonic plague

PLoS Pathogens
Vijay SivaramanWilliam E Goldman

Abstract

Pneumonic plague is the most rapid and lethal form of Yersinia pestis infection. Increasing evidence suggests that Y. pestis employs multiple levels of innate immune evasion and/or suppression to produce an early "pre-inflammatory" phase of pulmonary infection, after which the disease is highly inflammatory in the lung and 100% fatal. In this study, we show that IL-1β/IL-18 cytokine activation occurs early after bacteria enter the lung, and this activation eventually contributes to pulmonary inflammation and pathology during the later stages of infection. However, the inflammatory effects of IL-1β/IL-1-receptor ligation are not observed during this first stage of pneumonic plague. We show that Y. pestis also activates the induction of IL-1 receptor antagonist (IL-1RA), and this activation likely contributes to the ability of Y. pestis to establish the initial pre-inflammatory phase of disease.

References

Jul 1, 1995·Clinical Immunology and Immunopathology·E M O'NualláinD J Reen
Jan 1, 1997·Clinical Microbiology Reviews·R D Perry, J D Fetherston
Nov 14, 1997·The Journal of Experimental Medicine·T SchulteA Gessner
Oct 12, 2000·Biochemical and Biophysical Research Communications·X Q MaoJ M Hopkin
Nov 25, 2005·Proceedings of the National Academy of Sciences of the United States of America·Wyndham W LathemWilliam E Goldman
Nov 15, 2006·Infection and Immunity·Sarah S BubeckPeter H Dube
Dec 12, 2007·The Journal of Experimental Medicine·Fayyaz S SutterwalaRichard A Flavell
Jul 10, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Stephen B WillinghamJenny P-Y Ting
Jan 12, 2010·Current Opinion in Immunology·Eicke Latz
Feb 6, 2010·Proceedings of the National Academy of Sciences of the United States of America·Edward A MiaoAlan Aderem
Mar 5, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Katrin D Mayer-BarberAlan Sher
Mar 25, 2010·European Journal of Immunology·Sarah KimVeit Hornung
Jun 23, 2010·BMC Immunology·Angelene M CantwellPeter H Dube
Sep 30, 2010·Infection and Immunity·Jason E ComerB Joseph Hinnebusch
Dec 31, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Beckley K DavisJenny P-Y Ting
May 11, 2011·European Spine Journal : Official Publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society·Brian J C Freeman
Dec 14, 2011·American Journal of Physiology. Lung Cellular and Molecular Physiology·Louis R StandifordUrvashi Bhan
May 2, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Shanshan CaiSamithamby Jeyaseelan
May 9, 2012·Nature Medicine·Stephen T Holgate
Jul 31, 2012·Immunity·Gregory I VladimerEgil Lien
Dec 19, 2012·Cell Host & Microbe·Christopher N LaRock, Brad T Cookson
Mar 13, 2013·The Journal of Clinical Investigation·Taylor S Cohen, Alice S Prince
Oct 8, 2013·PLoS Pathogens·Roger D PechousWilliam E Goldman
Oct 12, 2013·Frontiers in Immunology·Charles A DinarelloGilles Kaplanski
Feb 4, 2014·The Journal of Immunology : Official Journal of the American Association of Immunologists·Kevin ShenderovAlan Sher
Mar 20, 2014·Infection and Immunity·Danielle L JessenMatthew L Nilles

❮ Previous
Next ❯

Citations

Dec 25, 2015·Trends in Microbiology·Roger D PechousWilliam E Goldman
Nov 29, 2016·Nature Reviews. Immunology·Akiko IwasakiRyan D Molony
May 14, 2016·Nature Reviews. Microbiology·Mary K Stewart, Brad T Cookson
Sep 11, 2019·Cold Spring Harbor Perspectives in Biology·Carolyn A Lacey, Edward A Miao
Jul 15, 2020·Annual Review of Microbiology·Katherine Andrea SchubertVictoria Auerbuch
Jan 24, 2016·The Journal of Immunology : Official Journal of the American Association of Immunologists·Vivien I Maltez, Edward A Miao
May 12, 2019·Scientific Reports·James S FindlayPetra C F Oyston
Jun 6, 2021·Redox Biology·Joanne Wei Kay Ku, Yunn-Hwen Gan
Oct 6, 2018·Alcohol·Brianna HarrisVijay Sivaraman

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA
PCR
flow cytometry

Software Mentioned

ImageJ

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Cell Wall Structure (ASM)

Bacterial cell walls are made of peptidoglycan (also called murein), which is made from polysaccharide chains cross-linked by unusual peptides containing D-amino acids. Here is the latest research on bacterial cell wall structures.

Bacterial Cell Wall Structure

Bacterial cell walls are made of peptidoglycan (also called murein), which is made from polysaccharide chains cross-linked by unusual peptides containing D-amino acids. Here is the latest research on bacterial cell wall structures.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.